A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Overview

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Full Title of Study: “A New Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)

Interventions

  • Drug: Primaquine

Clinical Trial Outcome Measures

Primary Measures

  • Difference in degree of hemolysis of G6PD(-) red blood cells in treated vs untreated matched samples.

Participating in This Clinical Trial

Inclusion:

  • Normal clinical evaluation – Willing and able to make all scheduled visits Exclusion: – pregnant or planning pregnancy – Have taken any anti-malarial medication in past month – Positive blood tests for HIV and specific types of hepatitis – Allergic to primaquine

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Walter Reed Army Institute of Research (WRAIR)
  • Overall Official(s)
    • Shon A Remich, Principal Investigator, WRAIR, Experimental Therapeutics

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.